Description: CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Home Page: www.cincor.com
CINC Technical Analysis
City Point
Waltham,
MA
02451
United States
Phone:
844 531 1834
Officers
| Name | Title |
|---|---|
| Mr. Marc M. P. de Garidel | CEO & Director |
| Dr. Mason W. Freeman M.D. | Chief Medical Officer |
| Ms. Catherine Pearce DHSc, M.B.A., MBA | Co-Founder & COO |
| Mr. Michael W. Kalb CPA | Exec. VP, CFO & Principal Accounting Officer |
| Ms. Ida Hatoum | Sr. VP and Head of People, Talent & Culture |
| Hema Keshava | Corp. Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0221 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-01-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |